Bayer (BAYN) Given a €128.00 Price Target at JPMorgan Chase & Co.

JPMorgan Chase & Co. set a €128.00 ($152.38) price target on Bayer (FRA:BAYN) in a report issued on Friday. The brokerage currently has a buy rating on the healthcare company’s stock.

Several other research firms have also recently issued reports on BAYN. Barclays set a €105.00 ($125.00) target price on shares of Bayer and gave the stock a sell rating in a research report on Monday, November 6th. Goldman Sachs Group set a €125.00 ($148.81) target price on shares of Bayer and gave the stock a buy rating in a research report on Tuesday, November 7th. UBS Group set a €125.00 ($148.81) target price on shares of Bayer and gave the stock a buy rating in a research report on Monday, November 6th. Berenberg Bank set a €124.00 ($147.62) target price on shares of Bayer and gave the stock a neutral rating in a research report on Friday, November 3rd. Finally, Jefferies Group set a €137.00 ($163.10) target price on shares of Bayer and gave the stock a buy rating in a research report on Tuesday, November 14th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. Bayer presently has a consensus rating of Buy and a consensus target price of €122.33 ($145.63).

Bayer (FRA:BAYN) traded down €0.40 ($0.48) during trading on Friday, hitting €104.00 ($123.81). 1,355,645 shares of the company’s stock traded hands. Bayer has a one year low of €97.91 ($116.56) and a one year high of €123.82 ($147.40). The firm has a market cap of $85,780.00 and a PE ratio of 27.88.

TRADEMARK VIOLATION WARNING: “Bayer (BAYN) Given a €128.00 Price Target at JPMorgan Chase & Co.” was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright legislation. The legal version of this piece of content can be read at https://www.com-unik.info/2017/12/30/bayer-bayn-given-a-128-00-price-target-at-jpmorgan-chase-co.html.

Bayer Company Profile

Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit